Rheumatoid Arthritis

Rheumatology Apps Not Ready for Prime Time. But ....

Experts and critics say the mobile apps designed for rheumatologists and their patients aren't good enough yet to be clinically useful. But there are reasons why you may have to learn about them anyway ...

Rheumatoid Arthritis

Articles in two different internal medicine journals last week discussed when and how to use opioids for rheumatologic pain, despite their hazards and limitations.

The JAK1 and JAK2 inhibitor baricitinib has shown significant results in a second Phase 3 trial for rheumatoid arthritis.

prior authorization

Prior authorizations have begun to spread pandemic-like from high-cost biologics to treatments used routinely in rheumatology. The time burden on rheumatologists is insupportable, contends the author, who says it's time to take action.

Two biosimilars for the TNF inhibitor infliximab are now licensed and distributed in Europe. A German rheumatologist wonders what difference the option to prescribe Inflektra and Remsima will make, if any.

FDA boxed warnings about hepatitis B virus (HBV) reactivation risk relate only to ofatumumab and rituximab. Eminent hepatologists say everyone destined for immunosuppression should be tested for HBV first.

Clinical remission is not necessarily good reason to stop treatment for rheumatoid arthritis. New MRI data show that many patients continue to show inflammation and osteitis, even if they no longer have symptoms.

The newer, injectable form of tocilizumab (Actemra) appears as safe and effective as the original intravenous version for treating rheumatoid arthritis unresponsive to other therapies.


Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.